会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 111. 发明授权
    • Extracellular rage binding protein (EN-RAGE) and uses thereof
    • 细胞外rage结合蛋白(EN-RAGE)及其用途
    • US07081241B1
    • 2006-07-25
    • US09167705
    • 1998-10-06
    • Ann Marie SchmidtDavid Stern
    • Ann Marie SchmidtDavid Stern
    • A61K39/395
    • A61K38/1703A01K2217/05C07K14/70503
    • The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a)(i) and the peptide of step (a)(ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the peptide of step (a) (i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
    • 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法,其包括:(a)混合:(i)RAGE肽或sRAGE肽或 片段,(ii)EN-RAGE肽或其片段,和(iii)化合物; (b)测量步骤(a)(i)的肽与步骤(a)(ii)的肽之间的相互作用水平,和(c)将步骤(b)中所发生的相互作用的量与测量的量进行比较 在步骤(a)(i)的肽和步骤(a)(ii)的肽之间,在不存在化合物的情况下,确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用 其中在化合物存在下相互作用量的减少表明该化合物能够抑制相互作用。 本发明还提供了一种抑制受试者的炎症的方法,其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物(RAGE)的相互作用,从而抑制受试者的炎症 学科。
    • 114. 发明申请
    • Digital media system with request-based merging of metadata from multiple databases
    • 数字媒体系统,具有来自多个数据库的元数据的基于请求的合并
    • US20050065912A1
    • 2005-03-24
    • US10653307
    • 2003-09-02
    • Charles CafrelliDavid SternF. Emerson
    • Charles CafrelliDavid SternF. Emerson
    • G06F17/30G06F7/00
    • G11B27/34G06F16/48G11B27/002G11B27/11G11B2220/2545G11B2220/2562G11B2220/41
    • A digital media system includes a changer control system that controls an optical disc changer. The changer control system includes a local database of metadata records containing information regarding the optical discs in the optical disc changer. The changer control system is also networked to a digital media server that stores digital media files. The digital media server includes a remote database of metadata records containing information regarding the digital media files. The changer control system provides a user interface that allows a user to access information regarding both the optical discs in the optical disc changer and the digital media files stored in the digital media server. To provide this information, a file system of the changer control system creates a merged set of selected metadata records from the local database and the remote database, in response to a request from the user interface.
    • 数字媒体系统包括控制光盘更换器的变换器控制系统。 更换器控制系统包括包含关于光盘更换器中的光盘的信息的元数据记录的本地数据库。 更换器控制系统还与存储数字媒体文件的数字媒体服务器联网。 数字媒体服务器包括元数据记录的远程数据库,其中包含有关数字媒体文件的信息。 更换器控制系统提供用户界面,其允许用户访问关于光盘更换器中的光盘和存储在数字媒体服务器中的数字媒体文件的信息。 为了提供该信息,更改器控制系统的文件系统响应于来自用户界面的请求,从本地数据库和远程数据库创建合并的一组选定的元数据记录。
    • 115. 发明申请
    • Methods for treating ischemic disorders using carbon monoxide
    • 使用一氧化碳治疗缺血性疾病的方法
    • US20050048133A1
    • 2005-03-03
    • US10679135
    • 2003-10-03
    • David PinskyDavid SternCharles Prestigiacome
    • David PinskyDavid SternCharles Prestigiacome
    • A61K38/00A61K38/48C07K14/705C07K16/28C12N9/64A61K33/00
    • C12N9/644A61K38/4846C07K14/70564C07K16/2854C12Y304/21022
    • The present invention provides for a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of a selectin antagonist in a sufficient amount over a sufficient time period to prevent white blood cell accumulation so as to treat the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject carbon monoxide gas in a sufficient amount over a sufficient period of time thereby treating the ischemic disorder in the subject. The invention further provides a method for treating an ischemic disorder in a subject which comprises administering to the subject a pharmaceutically acceptable form of inactivated Factor IX in a sufficient amount over a sufficient period of time to inhibit coagulation so as to treat the ischemic disorder in the subject.
    • 本发明提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内以足够量的时间向所述受试者施用药学上可接受的形式的选择素拮抗剂,以防止白血细胞积聚,从而治疗缺血性 主题无序。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内向受试者施用足够量的一氧化碳气体,从而治疗受试者的缺血性疾病。 本发明进一步提供了一种治疗受试者的缺血性疾病的方法,其包括在足够的时间内以足够的时间向受试者施用药学上可接受的形式的灭活因子IX以抑制凝血,以便治疗缺血性障碍 学科。
    • 117. 发明授权
    • Extracellular novel RAGE binding protein (EN-RAGE) and uses thereof
    • 细胞外新型RAGE结合蛋白(EN-RAGE)及其用途
    • US06670136B2
    • 2003-12-30
    • US09826589
    • 2001-04-05
    • Ann Marie SchmidtDavid Stern
    • Ann Marie SchmidtDavid Stern
    • G01N3353
    • C07K14/70503A01K2217/05A61K38/00
    • The present invention provides for an isolated human EN-RAGE peptide. The present invention also provides for a method for determining whether a compound is capable of inhibiting the interaction of an EN-RAGE peptide with a RAGE peptide, which comprises: (a) admixing: (i) a RAGE peptide or an sRAGE peptide or a fragment of either thereof, (ii) an EN-RAGE peptide or a fragment thereof, and (iii) the compound; (b) measuring the level of interaction between the peptide of step (a) (i) and the peptide of step (a) (ii), and (c) comparing the amount of interaction meausred in step (b) with the amount measured between the petpide of step (a)(i) and the peptide of step (a) (ii) in the absence of the compound, thereby determining whether the compound is capable of inhibiting the interaction of the EN-RAGE peptide with the RAGE peptide, wherein a reduction in the amount of interaction in the presence of the compound indicates that the compound is capable of inhibiting the interaction. The present invention also provides for a method for inhibiting inflammation in a subject which comprises administering to the subject a compound capable of interfering with the interaction between EN-RAGE peptide and receptor for advanced glycation endproduct (RAGE) in the subject thereby inhibiting inflammation in the subject.
    • 本发明提供了分离的人类EN-RAGE肽。 本发明还提供了一种用于确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用的方法,其包括:(a)混合:(i)RAGE肽或sRAGE肽或 片段,(ii)EN-RAGE肽或其片段,和(iii)化合物; (b)测量步骤(a)(i)的肽与步骤(a)(ii)的肽之间的相互作用水平,和(c)将步骤(b)中所发生的相互作用的量与测量的量进行比较 在不存在化合物的情况下,步骤(a)(i)的petpide和步骤(a)(ii)的肽之间,从而确定化合物是否能够抑制EN-RAGE肽与RAGE肽的相互作用 其中在化合物存在下相互作用量的减少表明该化合物能够抑制相互作用。 本发明还提供了一种抑制受试者的炎症的方法,其包括向受试者施用能够干扰受试者的EN-RAGE肽和受体之间相互作用的晚期糖基化终产物(RAGE)的相互作用,从而抑制受试者的炎症 学科。
    • 120. 发明授权
    • Methods involving direct write optical lithography
    • 包括直写光刻技术的组成和方法
    • US06480324B2
    • 2002-11-12
    • US09880058
    • 2001-06-14
    • Calvin F. QuateDavid Stern
    • Calvin F. QuateDavid Stern
    • G02B2608
    • G03F7/70291B01J19/0046B01J2219/00353B01J2219/00439B01J2219/00527B01J2219/00529B01J2219/00585B01J2219/0059B01J2219/00596B01J2219/00605B01J2219/00608B01J2219/00612B01J2219/00617B01J2219/00626B01J2219/00637B01J2219/00659B01J2219/00689B01J2219/00711B01J2219/00722B01J2219/00725B82Y30/00C40B40/06C40B60/14G03F7/70283G03F7/704
    • An improved optical photolithography system and method provides predetermined light patterns generated by a direct write system without the use of photomasks. The Direct Write System provides predetermined light patterns projected on the surface of a substrate (e.g., a wafer) by using a computer controlled component for dynamically generating the predetermined light pattern, e.g., a spatial light modulator. Image patterns are stored in a computer and through electronic control of the spatial light modulator directly illuminate the wafer to define a portion of the polymer array, rather than being defined by a pattern on a photomask. Thus, in the Direct Write System each pixel is illuminated with an optical beam of suitable intensity and the imaging (printing) of an individual feature is determined by computer control of the spatial light modulator at each photolithographic step without the use of a photomask. The Direct Write System including a spatial light modulator is particularly useful in the synthesis of DNA arrays and provides an efficient element for polymer array synthesis by using spatial light modulators to generate a predetermined light pattern that defines the image patterns of a polymer array to be deprotected.
    • 改进的光学光刻系统和方法提供由直接写入系统产生的预定光图案,而不使用光掩模。 直接写入系统通过使用用于动态生成预定光图案的计算机控制部件(例如空间光调制器)来提供投影在基板(例如,晶片)的表面上的预定光图案。 图像图案存储在计算机中,并且通过空间光调制器的电子控制直接照亮晶片以限定聚合物阵列的一部分,而不是由光掩模上的图案限定。 因此,在直写系统中,每个像素用适当强度的光束照射,并且通过在每个光刻步骤的计算机控制空间光调制器而不使用光掩模来确定单个特征的成像(打印)。 包括空间光调制器在内的直接写入系统在DNA阵列的合成中特别有用,并且通过使用空间光调制器产生限定要去保护的聚合物阵列的图像图案的预定光图案,为聚合物阵列合成提供有效元素 。